Important Safety Information

Important Safety Information

Indication:

AGGRASTAT® is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

IMPORTANT SAFETY INFORMATION

Contraindications:

Known hypersensitivity to any component of Aggrastat.
History of thrombocytopenia with prior exposure to Aggrastat.
Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

Bleeding is the most common complication encountered during therapy with AGGRASTAT. Most bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, oral anticoagulants and antiplatelet drugs increases the risk of bleeding.

Adverse Reactions:

Bleeding is the most commonly reported adverse reaction.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This application is intended for United States healthcare professionals only.

Aggrastat, registered trademark of Medicure International, Inc. Copyright 2016 Medicure Incorporated. All rights reserved.

Browse the App Page archive. Bookmark the permalink.